We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03481842
Recruitment Status : Withdrawn (Change in study design and sponsor)
First Posted : March 29, 2018
Last Update Posted : October 29, 2021
Sponsor:
Information provided by (Responsible Party):
BioGene Pharmaceutical Ltd.

Brief Summary:

Background:

Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.

Types of endometriosis:

Endometriosis is divided into genital and extragenital. Genital endometriosis is internal and external. When the inner is affected by the uterus, with the external - the ovaries, tubes, vagina and external genital organs are affected. Extragenital endometriosis can affect various organs of the abdominal cavity.

Drug treatment does not show high effectiveness. Surgery / laparoscopic is currently considered the gold standard treatment for this problem, including infertility treatment.

The purpose of our studies is to achieve substantial results with respect to tolerability, safety and clinical efficacy of vaginal suppository ELTA for treatment of the endometriosis.

Methods:

Phase I clinical trial to be conducted at Cancer Center to hold under the aegis UniversitätsSpital Zürich from May 2018 to September 2018.

Ninety-four patients with the form of genital endometriosis will take part in the studies. The study was approved by the Ethics Committee at the Cancer Institute no C99884.01FH339


Condition or disease Intervention/treatment Phase
Endometriosis Endometriosis Ovary Endometriosis Externa Endometriosis, Rectum Biological: Linifanib Drug: BIBW2992 Drug: Axitinib Phase 1 Phase 2

Detailed Description:

The composition of the endometrium includes epithelial cell layers lining the uterine cavity, and deeper stroma, including the secretory glands. Each layer is characterized by the presence of a large number of blood vessels, through which a sufficient amount of blood is delivered. A large number of these vessels and arteries go to the surface layers due to myometrium and form a capillary network in the stroma.

In the vaginal suppositories, the investigators applied minimally therapeutic doses of inhibitors of neoangiogenesis, as well as other components that caused the pathological growth of the endometrium.

Anti-angiogenic therapy - inhibition of proliferative processes in the vascular wall of capillaries and small vessels in the endometrium, is the determining factor of the therapeutic effect of endometriosis when treated with vaginal suppositories.

The composition of the suppository:

  • Axitinib, Afatinib, Linifanib (ABT-869) in a minimally sufficient therapeutic doses
  • Auxiliary substances that ensure a uniform release of active components from suppositories, taking into account the dependence of this process on the chemical nature of the basis, surfactant, dissolution medium.

(the composition and amount of excipients are maximally optimal for bioavailability of drugs from suppositories, taking into account the pharmacokinetics, pharmacodynamics and synergy of active drugs) This therapy has a slight teratogenic effect, which should be taken into account when planning pregnancy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Single application in the morning of a vaginal suppository ELTA:

Five days per week (with a treatment-free interval of two days in a row.) e.g. Monday and Tuesday - treatment-free days.

Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
Estimated Study Start Date : October 10, 2021
Estimated Primary Completion Date : October 10, 2021
Estimated Study Completion Date : October 10, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis

Arm Intervention/treatment
Experimental: Vaginal Suppositories

Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA

The composition of the suppository:

  • Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose
  • Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose
  • Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose
Biological: Linifanib
in a minimally sufficient therapeutic dose
Other Name: ABT869

Drug: BIBW2992
in a minimally sufficient therapeutic dose
Other Names:
  • Afatinib
  • Giotrif

Drug: Axitinib
in a minimally sufficient therapeutic dose
Other Names:
  • AG013736;
  • Inlyta




Primary Outcome Measures :
  1. Local tolerability of the vaginal suppository ELTA defined as a cumulative sum of clinical signs for each patient [ Time Frame: 6 weeks ]

    Local tolerability of the vaginal suppositories ELTA will be defined as a cumulative sum score of the solicited local /vaginal (consisting of subjectively experienced symptoms rated by the patient: burning, itching, bleeding, pain, dryness and objectively documented findings rated by the physician: redness, petechial bleeding, dryness, swelling) for each patient after every weeks of application (scored from 0 [none/normal] to 5 [severe]) Weekly visit of patients every seventh day from the beginning of treatment.

    SCALE EVALUATION EVENTS

    • burning - 2 points,
    • dryness - 1 point,
    • painful symptom- 3 points,
    • itching - 1 point,
    • bleeding - 5 points,

    If there is bleeding or the development of edema - the study for the patient will be stopped.



Secondary Outcome Measures :
  1. Subjective symptoms (local tolerability) [ Time Frame: 7 weeks ]
    Each of the subjective symptoms (scored from 0 [none/normal] to 5 [severe]) from the first visit (after the first application)/ A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)


Other Outcome Measures:
  1. Objective findings [ Time Frame: 7 weeks ]

    Each of the objective symptoms (scored from 0 [none/normal] to 3 [severe]) from the first visit (after the first application).

    • dryness, itching, hyperemia of the perineum - 1 point,
    • pain syndrome with itching / dryness or without - 2 points,
    • bleeding with pain syndrome (or other symptoms / without them - 3 points,

    A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)


  2. Global judgement of tolerability [ Time Frame: 4 weeks ]
    Global judgement of tolerability by investigator and patients. The scores of the Clinical Global Impression (CGI) Scale.

  3. Safety evaluation of therapy [ Time Frame: 15 weeks ]
    Safety evaluation of therapy. Drugs safety will be evaluated by assessment of adverse events ( ADRs).

  4. Serious Adverse Event. [ Time Frame: up to 15 weeks ]
    Occurrence of AE / SAE / ADE / SADE. Characteristics of occured AE / SAE / ADE / SADE

  5. Change in pH-value from vaginal smear [ Time Frame: up to 6 weeks ]
    pH-value from vaginal smear at every visit for each patient after the 3rd and 6th week of application of suppositories.

  6. Change in Vaginal flora [ Time Frame: up to 15 weeks ]
    Vaginal flora (Lactobacillus spp., Atopobium vaginae and Gardnerella vaginalis) on the first day of intake (before using the first suppository) and on the day of termination of therapy

  7. Other signs of assessing the hip therapy [ Time Frame: up to 15 weeks ]

    Mandatory Clinical blood test for each patient after the 3rd and 6th week of application of suppositories.

    A control blood test on the first day of the 15th week after the start of the first suppository




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • verification of endometriosis
  • signed agreement of informed consent
  • agreement with information on the nature, relevance and scope of the investigation, as well as the expected results and undesirable consequences of IMD

Exclusion Criteria:

  • use of not permitted contraception or not willing to use contraception
  • pregnancy or lactation
  • planned pregnancy in the next 36 months with the consent to participate in that clinical trial
  • use of any other intravaginal medicinal product or medical device
  • known hypersensitivity to one or more of the active and / or inactive ingredients
  • acute or chronic renal failure
  • acute or chronic heart failure
  • the patient's reluctance to follow the trial protocol
  • chronic alcoholism
  • drug addiction
  • use of antidepressants (during participation in trial)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03481842


Locations
Layout table for location information
Switzerland
BioGene Pharmaceutical Ltd.
Basel, Вâlе, Switzerland, 4057
Sponsors and Collaborators
BioGene Pharmaceutical Ltd.
Layout table for additonal information
Responsible Party: BioGene Pharmaceutical Ltd.
ClinicalTrials.gov Identifier: NCT03481842    
Other Study ID Numbers: C99884.337/18
First Posted: March 29, 2018    Key Record Dates
Last Update Posted: October 29, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioGene Pharmaceutical Ltd.:
Endometriosis
VEGF(R)
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometriosis
Axitinib
Afatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action